TY - JOUR
T1 - Precision oncology decision support
T2 - Current approaches and strategies for the future
AU - Kurnit, Katherine C.
AU - Ileana Dumbrava, Ecaterina E.
AU - Litzenburger, Beate
AU - Khotskaya, Yekaterina B.
AU - Johnson, Amber M.
AU - Yap, Timothy A.
AU - Rodon, Jordi
AU - Zeng, Jia
AU - Shufean, Md Abu
AU - Bailey, Ann M.
AU - Sanchez, Nora S.
AU - Holla, Vijaykumar
AU - Mendelsohn, John
AU - Shaw, Kenna Mills
AU - Bernstam, Elmer V.
AU - Mills, Gordon B.
AU - Meric-Bernstam, Funda
N1 - Funding Information:
This work was supported in part by 1U01 CA180964 (F. Meric-Bernstam and E.V. Bernstam), NIH Research Training Grant T32 CA101642 (K.C. Kurnit), The Cancer Prevention and Research Institute of Texas (RP150535; to F. Meric-Bernstam, E.V. Bernstam, A.M. Johnson, J. Zeng, A.M. Bailey, V. Holla, N.S. Sánchez, and K.M. Shaw), the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (F. Meric-Bernstam, G.B. Mills, B. Litzenburger, A.M. Johnson, Y.B. Khotskaya, J. Zeng, M.A. Shufean, A.M. Bailey, N.S. Sánchez, V. Holla, J. Mendelsohn, and K.M. Shaw), NCATS GrantUL1 TR000371 (Center for Clinical and Translational Sciences; to F. Meric-Bernstam and E.V. Bernstam), The Bosarge Family Foundation (A.M. Bailey, V. Holla, J. Zeng, and G.B. Mills), and The University of Texas MD Anderson Cancer Center Support Grant (P30 CA016672; to F. Meric-Bernstam).
Funding Information:
J. Rodon reports receiving commercial research grants from Bayer and Novartis and is a consultant/advisory board member for Lilly, Novartis, Orion, Peptomyc, and Servier. E.V. Bernstam reports receiving commercial research grants from Aileron, AstraZeneca, Bayer, Boehringer Ingelheim, Calithera, Curis, CytoMx, Debiopharm, Effector Therapeutics, Genentech, Novartis, Pfizer, Puma, Taiho, and Zymeworks and is a consultant/advisory board member for Clearlight Diagnostics, Darwin Health, Dialecta, GRAIL, Inflection Biosciences, Pieris, and Sumitomo Dainippon Pharma. G.B. Mills reports receiving commercial research grants from AstraZeneca, Critical Outcome Technologies, Illumina, Karus, Nanostring, Pfizer, and Takeda/Millenium Pharmaceuticals, reports receiving speakers bureau honoraria from Allostery, AstraZeneca, ImmunoMet, ISIS Pharmaceuticals, Lilly, MedImmune, Novartis, Pfizer, Sym-phogen, and Tarveda, holds ownership interest (including patents) in Catena Pharmaceuticals, ImmunoMet, Myriad Genetics, PTV Ventures, and Spindletop Ventures, and is a consultant/advisory board member for Adventist Health, Allostery, AstraZeneca, Catena Pharmaceuticals, Critical Outcome Technologies, ImmunoMet, ISIS Pharmaceuticals, Lilly, MedImmune, Novartis, Precision Medicine, Provista Diagnostics, Signalchem Lifesciences, Symphogen, Takeda/ Millenium Pharmaceuticals, Tarveda, and Tau Therapeutics. F. Meric-Bernstam reports receiving commercial research grants from Aileron, AstraZeneca, Bayer, Calithera, Curis, CytoMx, Debio, eFFECTOR, Genentech, Jounce, Novartis, Pfizer, Puma, Taiho, and Zymeworks and is a consultant/advisory board member for Clearlight Diagnostics, Darwin Health, Dialecta, GRAIL, Inflection Biosciences, Pieris, and Sumitomo Dainippon. No potential conflicts of interest were disclosed by the other authors.
Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2018/6/15
Y1 - 2018/6/15
N2 - With the increasing availability of genomics, routine analysis of advanced cancers is now feasible. Treatment selection is frequently guided by the molecular characteristics of a patient's tumor, and an increasing number of trials are genomically selected. Furthermore, multiple studies have demonstrated the benefit of therapies that are chosen based upon the molecular profile of a tumor. However, the rapid evolution of genomic testing platforms and emergence of new technologies make interpreting molecular testing reports more challenging. More sophisticated precision oncology decision support services are essential. This review outlines existing tools available for health care providers and precision oncology teams and highlights strategies for optimizing decision support. Specific attention is given to the assays currently available for molecular testing, as well as considerations for interpreting alteration information. This article also discusses strategies for identifying and matching patients to clinical trials, current challenges, and proposals for future development of precision oncology decision support.
AB - With the increasing availability of genomics, routine analysis of advanced cancers is now feasible. Treatment selection is frequently guided by the molecular characteristics of a patient's tumor, and an increasing number of trials are genomically selected. Furthermore, multiple studies have demonstrated the benefit of therapies that are chosen based upon the molecular profile of a tumor. However, the rapid evolution of genomic testing platforms and emergence of new technologies make interpreting molecular testing reports more challenging. More sophisticated precision oncology decision support services are essential. This review outlines existing tools available for health care providers and precision oncology teams and highlights strategies for optimizing decision support. Specific attention is given to the assays currently available for molecular testing, as well as considerations for interpreting alteration information. This article also discusses strategies for identifying and matching patients to clinical trials, current challenges, and proposals for future development of precision oncology decision support.
UR - http://www.scopus.com/inward/record.url?scp=85051820903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051820903&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-17-2494
DO - 10.1158/1078-0432.CCR-17-2494
M3 - Review article
C2 - 29420224
AN - SCOPUS:85051820903
SN - 1078-0432
VL - 24
SP - 2719
EP - 2731
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -